© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Study Investigates Hydroxychloroquine and Itraconazole in Ovarian Cancer
July 28, 2020
Ainhoa Madariaga, MD, discusses the data from the phase 1/2 HYDRA-01 trial looking at hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer.
Responses Observed With Poziotinib in HER2-Positive Non-Small Cell Lung Cancer
July 28, 2020
"We believe that poziotinib is a significant advancement for patients with this deadly disease in an area of high unmet medical need."
Sunitinib Generates Clinical Activity After Immunotherapy Failure in Metastatic Renal Cell Carcinoma
July 28, 2020
Second-line sunitinib demonstrated clinical activity after failure on frontline immunotherapy in patients with metastatic renal cell carcinoma.
New Treatment Approach for Newly Diagnosed Glioblastoma Shows Early Signs of Safety, Efficacy
July 28, 2020
In an interview with Targeted Oncology, David Reardon, MD, discussed the background and findings for the phase 1/2 clinical trial of INO-5401 and INO-9012 plus cemiplimab in patients with newly diagnosed glioblastoma.
Larotrectinib Is Well-Tolerated in Metastatic Solid Tumors
July 28, 2020
Marcia Brose, MD, PhD, discusses the safety findings from an analysis of larotrectinib as treatment of patients with metastatic solid tumors.
Advancing Survival in Relapsed/Refractory Multiple Myeloma
July 28, 2020
A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.
FDA Grants Fast Track Designation to CMP-001 Combination in Advanced Melanoma
July 27, 2020
The FDA has granted Fast Track designation to CMP-001 in combination with nivolumab plus ipilimumab under 2 melanoma indications.
Results of Pooled Analysis Show Positive Data for Trilaciclib in ES-SCLC
July 27, 2020
Jared Weiss, MD, discusses the pooled analysis of 3 phase 2 trials looking at trilaciclib in patients with extensive-stage small cell lung cancer.
Hoffman Explores Frontline Treatments in CLL
July 27, 2020
Marc Hoffman, MD, reviewed a case of a 61-year-old man with chronic lymphocytic leukemia, during a virtual Case Based Peer Perspectives event.
Hematopoietic Cell Transplant Reduces Rate of Relapse in Patients With Waldenström Macroglobulinemia
July 27, 2020
“Given that the majority of the data analyzed in the study came from patients with relapsed/refractory disease, both autologous hematopoietic cell transplantation and allogeneic hematopoietic cell transplantation afford relatively high complete response rates when compared with established chemo-immunotherapy regimens and novel agents."
Promising Data Follow on First Targeted Therapy Approval in Biliary Tract Cancer
July 27, 2020
Like never before, presentations related to systemic therapies for biliary tract cancers are taking center stage at medical and oncology conferences, generating hope that treating physicians will have multiple options in the near future.
A 69-Year-Old Woman With Advanced Renal Cell Carcinoma
July 27, 2020
An expert oncologist presents the case of a 69-year-old woman with advanced renal cell carcinoma, and considers available treatment options for patients with a similar disease setting.